Goldman Sachs: Hansoh Pharmaceutical (03692.HK) expands ADC collaboration with Roche, enhancing visibility of global value monetization; target price HK$52.7

Zhitong Finance APP has learned that Goldman Sachs issued a research report stating that Hansoh Pharmaceutical (03692.HK) announced the signing of a strategic collaboration and license agreement with Roche, marking the company's first platform-based collaboration; the bank maintains its positive view on Hansoh Pharmaceutical and reiterates its "Buy" rating with a target price of HK$52.7.